{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:15:28Z","timestamp":1761743728869},"reference-count":11,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis Supplements"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.atherosclerosissup.2012.10.030","type":"journal-article","created":{"date-parts":[[2013,1,26]],"date-time":"2013-01-26T17:32:52Z","timestamp":1359221572000},"page":"199-202","source":"Crossref","is-referenced-by-count":24,"title":["Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis"],"prefix":"10.1016","volume":"14","author":[{"given":"Katrin","family":"Klein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caner","family":"S\u00fcsal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian M.","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Eduardo","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Beimler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vedat","family":"Schwenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Zeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schemmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Macher-Goeppinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Opelz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Morath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosissup.2012.10.030_bib1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1012376","article-title":"Desensitization in HLA-incompatible kidney recipients and survival","volume":"365","author":"Montgomery","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosissup.2012.10.030_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2215\/CJN.01651105","article-title":"Presensitization: the problem and its management","volume":"1","author":"Jordan","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.030_bib3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1432-2277.2012.01490.x","article-title":"Prevention of antibody-mediated kidney transplant rejection","volume":"25","author":"Morath","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.atherosclerosissup.2012.10.030_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosissup.2012.10.030_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00007890-199308000-00015","article-title":"Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients","volume":"56","author":"Glotz","year":"1993","journal-title":"Transplantation"},{"key":"10.1016\/j.atherosclerosissup.2012.10.030_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1399-0039.2011.01638.x","article-title":"Current approaches to the management of highly sensitized kidney transplant patients","volume":"77","author":"S\u00fcsal","year":"2011","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.atherosclerosissup.2012.10.030_bib7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1432-2277.2012.01447.x","article-title":"Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy","volume":"25","author":"Morath","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.atherosclerosissup.2012.10.030_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/TP.0b013e3181ea3985","article-title":"An integrative approach for the transplantation of high-risk sensitized patients","volume":"90","author":"Morath","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.atherosclerosissup.2012.10.030_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/TP.0b013e3182100f77","article-title":"No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report","volume":"91","author":"S\u00fcsal","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.atherosclerosissup.2012.10.030_bib10","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/j.1600-6143.2009.02800.x","article-title":"De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure","volume":"9","author":"Hidalgo","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.atherosclerosissup.2012.10.030_bib11","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1681\/ASN.2008101037","article-title":"Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients","volume":"20","author":"Noel","year":"2009","journal-title":"J Am Soc Nephrol"}],"container-title":["Atherosclerosis Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568812000414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568812000414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T05:32:14Z","timestamp":1539927134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567568812000414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1567568812000414"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2012.10.030","relation":{},"ISSN":["1567-5688"],"issn-type":[{"value":"1567-5688","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}